  There is an unmet need to develop medications or drug combinations which can
stop advancement of NASH to liver cirrhosis and HCC. Therefore, identifying key
biomarkers based on overall survival and the exploring biological processes
involved in the pathogenesis and progression of NASH toward cirrhosis and HCC
to improve therapeutic interventions is necessary. The microarray dataset from
the GPL13667 platform was downloaded from the Gene Expression Omnibus (GEO).
The inclusion criteria for the DEGs included an adjusted p-value <0.05 and a
log(2) fold change >1. In the first step, protein-protein interaction (PPI)
network of differentially expressed genes (DEGs) in every three groups (NASH,
Cirrhosis and HCC) was constructed using STRING online database. In the second
step, the DEGs of each group were imported to Cytoscape software separately,
and the genes with Degree >3 were selected. In the third step, the genes with
Degree >3 were imported to Gephi software (0.9.2 version) and the genes with
betweenness centrality >0 were selected. Venn diagram of these genes was
depicted for the NASH, cirrhotic and HCC groups. According to venn diagram, 96
(NASH), 30 (cirrhotic) and 213 (HCC) genes were specifically upregulated (based
on inclusion criteria). Among specific genes, 22 (NASH), 5 (cirrhotic) and 82
(HCC) genes were with poor overall survival. The overlap among the 3 groups
(NASH, Cirrhosis and HCC) contained 4 upregulated genes HLA-F, HLA-DPA1, TPM1
and YWHAZ. From 4 upregulated genes, only YWHAZ gene was with poor overall
survival. The present study detected new candidate genes and key biological
processes in NASH, cirrhosis and HCC based on overall survival and using in
silico analysis. Therefore, performing in vitro and in vivo researches to
verify the results is necessary.
